The Comprehensive Cancer Center at the University of Michigan has the largest pediatric oncology research effort in Michigan, providing comprehensive care for children with cancer, including leukemia, lymphoma, brain tumors, neuroblastoma and Wilm's tumor.
The Pediatric Hemophilia and Coagulation Disorders Program provides comprehensive, coordinated assessment and management of health services for individuals with complex hemostatic and thrombotic disorders.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that affects about one in 5,000 people and commonly causes nosebleeds, with more frequent nosebleeds typically starting after about age 12. Patients with HHT have a tendency to form blood vessels that are abnormal, fragile, and bleed more easily. Michigan Medicine has a multidisciplinary team of physicians to treat HHT, including specialists in otolaryngology (for nosebleeds), pulmonary diseases, interventional radiology, gastroenterology, neurosurgery, liver diseases, cardiology, heart failure, dermatology, radiation oncology, hematology-oncology and associated pediatric subspecialties.
There are many different specialists who treat patients with HHT. Many patients will eventually see two or more types of specialists, especially later in adulthood. Specialists who treat HHT include otolaryngologists (ear, nose & throat doctors), interventional radiologists (to treat AVMs), hematologists (to help manage anemia), and more.
